
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Surrounded
Author(s)Wayne Koberstein
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Advertisement
Articles in this issue
almost 25 years ago
Research: New Horizonsalmost 25 years ago
Earnings: Tough Times Aheadalmost 25 years ago
Outbreak: Anthrax Alarmalmost 25 years ago
Patents: China on the Genome Mapalmost 25 years ago
Privacy, Pediatrics, and Policyalmost 25 years ago
Lilly's International Familyalmost 25 years ago
Update: Punishment and Reprievealmost 25 years ago
Shortage: Vaccine Worriesalmost 25 years ago
Gateway to JapanNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
The Cost of Fixing Pharma
5





